SynthesisJournal of substance abuse treatment2014
Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies.
Synthesis in Journal of substance abuse treatment, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 4 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Extended-release naltrexone versus oral naltrexone for substance use disorders: A systematic review and meta-analysis.Drug and alcohol dependence · 2025Pooled it
- Extended-release pharmacotherapies for substance use disorders in incarcerated populations: A systematic review.Addiction (Abingdon, England) · 2025Pooled it
- Economic Evaluations of Opioid Use Disorder Interventions.PharmacoEconomics · 2016Pooled it
- Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis.Journal of addiction medicinePooled it
- Single-dose intravenous ketamine or intramuscular naltrexone for high-utilization inpatients with alcohol use disorder: pilot trial feasibility and readmission rates.Addiction science & clinical practice · 2022Trial
- Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial.The lancet. Psychiatry · 2021Trial
- Trial
- Effects of naltrexone are influenced by childhood adversity during negative emotional processing in addiction recovery.Translational psychiatry · 2017Trial
- An organizational readiness intervention and randomized controlled trial to test strategies for implementing substance use disorder treatment into primary care: SUMMIT study protocol.Implementation science : IS · 2015Trial
- Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone.Drug and alcohol dependence · 2015Trial
- Real-world comparative effects of slow-release oral morphine vs. methadone on healthcare use for opioid use disorder: A population-based target trial emulation.Addiction (Abingdon, England) · 2026Article
- Follow-up and reasons for extended-release naltrexone discontinuation for alcohol use disorder after hospital initiation.BMJ open quality · 2024Article
- Pharmacist-Driven Alcohol Use Disorder Screening May Increase Inpatient Utilization of Extended-Release Naltrexone: A Single Center Pilot Study.Pharmacy (Basel, Switzerland) · 2024Article
- Scanning Analysis of Sequential Semisolvent Vapor Impact To Study Naltrexone Release from Poly(lactide-co-glycolide) Microparticles.Molecular pharmaceutics · 2022Article
- Mechanism of opioid addiction and its intervention therapy: Focusing on the reward circuitry and mu-opioid receptor.MedComm · 2022Review
- Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial.Alcoholism, clinical and experimental research · 2021Article
- Nicotine and Opioids: a Call for Co-treatment as the Standard of Care.The journal of behavioral health services & research · 2020Review
- Alcohol and Pain: A Translational Review of Preclinical and Clinical Findings to Inform Future Treatment Strategies.Alcoholism, clinical and experimental research · 2020Review
- Access to treatment for alcohol use disorders following Oregon's health care reforms and Medicaid expansion.Journal of substance abuse treatment · 2018Article
- State-Targeted Funding and Technical Assistance to Increase Access to Medication Treatment for Opioid Use Disorder.Psychiatric services (Washington, D.C.) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
Abstract
Through improved adherence, once-monthly injectable extended-release naltrexone (XR-NTX) may provide an advantage over other oral agents approved for alcohol and opioid dependence treatment. The objective of this study was to evaluate cost and utilization outcomes between XR-NTX and other pharmacotherapies for treatment of alcohol and opioid dependence. Published studies were identified through comprehensive search of two electronic databases. Studies were included if they compared XR-NTX to other approved medicines and reported economic and healthcare utilization outcomes in patients with opioid or alcohol dependence. We identified five observational studies comparing 1,565 patients using XR-NTX to other therapies over 6 months. Alcohol dependent XR-NTX patients had longer medication refill persistence versus acamprosate and oral naltrexone. Healthcare utilization and costs was generally lower or as low for XR-NTX-treated patients relative to other alcohol dependence agents. Opioid dependent XR-NTX patients had lower inpatient substance abuse-related utilization versus other agents and $8170 lower total cost versus methadone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.